Register for our S/EIS Fund

A passion for


We are constantly innovating our people, project management and technology models leading to outstanding results for our collaborators. The world’s first app based technology platform Chemistry in the cloudTM enables us to work together to make faster decisions. Our deep understanding that an early and intensive evaluation of target molecules based on real insight into the science will lead to faster downstream execution. The result is a higher throughput of successful drug-like compounds.

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

ADME screening services


In vitro facilities at o2h discovery provide ADME (absorption, distribution, metabolism, excretion) to provide faster and improved decision making points for our chemistry clients or standalone offering to support drug discovery programs.

We offer cost-efficient standardized and customized assays as per the client’s requirement for ADME parameters. Our ADME capabilities include:

ADME Assays

  • Physicochemical screening
    • Aqueous solubility (Thermodynamic & Kinetic)
    • Log P
    • Log D
  • Drug Metabolism
    • Microsomal Stability
    • Plasma Stability
    • Hepatocyte Stability
  • Protein Binding
    • Plasma Protein Binding
  • Permeability
    • PAMPA
  • Drug-Drug interaction
    • CYP inhibition assays (Fluorescent and LCMS/MS)

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

In vitro assays


In vitro facilities at o2h discovery have been developed to provide faster decision-making points for our chemistry clients.

We have doubled both our capacity as well as capability to include a range of pharmacology services to evaluate activity and/or potential liability of compounds. Our purpose-built labs include industry standard formats of fluorescence, luminescence and absorbance to help develop and optimise biochemical and/or cellular assays in a range of therapeutic areas.

o2h discovery offers:

ADME Assays
Solubility (thermodynamic, kinetic), Log P/Log D studies, permeability (PAMPA), CYP inhibition (fluorescence, LCMS/MS based), microsomal stability, plasma stability, hepatocyte stability, plasma protein binding.

Target-based Assays
Enzymatic/kinase assays, binding assays, GPCR assays

Cell-based Assays
ELISA, proliferation/cytotoxicity, phosphorylation status, cytokine production assays using hPBMCs, signal transduction assays.

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

In vivo studies


o2h discovery has an in-depth expertise in performing standard bioavailability/tissue-distribution PK studies, acute/chronic toxicology studies as well as pathophysiologically relevant experimental models for multiple therapeutic indications.

The macroscopic observations can be corroborated with a range of different techniques including but not limited to histopathological analysis, estimation of haematological and/or biochemical parameters etc. Currently, the in-vivo experiments are performed only with rodents (e.g, mice, rats). Our in-vivo models are available on a fee-for-service basis as well as a part of an integrated biology project. We also have the capability to customise these models as per client requirement. In-vivo studies are done in conjunction with CROs with whom o2h has a preferred relationship for the past several years.

Examples of in vivo models include

  • Collagen-induced arthritis
  • Adjuvant-induced arthritis
  • DSS-induced colitis
  • TNBS-induced colitis
  • PMA-induced psoriasis/atopic dermatitis
  • IMQ-induced psoriasis/atopic dermatitis
  • Cytokine release assay
  • Single dose acute toxicity
  • Repeat dose toxicity study
  • Oral bioavailability study

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

Integrated drug discovery


The ultimate metric to measure the success of Integrated Drug Discovery (IDD) project is the capacity to create intellectual property and value to our customers (e.g., identification of a lead compound demonstrating low nM activity under in vitro conditions and exhibiting statistically significant in vivo efficacy in a pathophysiologically-relevant disease model).

Successful IDD projects rely on efficient integration of various disciplines, medicinal chemistry experience, operational excellence and a pragmatic approach. o2h discovery has taken a modular approach while establishing its IDD services to offer our clients maximum flexibility in their outsourcing decision.

Each of the varied module of the drug discovery process is available as a unique point of entry individually as a subset of services or as the traditional drug discovery pathway from hit identification through to lead generation and beyond. Our expertise includes – medicinal chemistry, hit identification, lead generation/optimisation, computational chemistry, in-vitro enzymatic and cell-based screening, DMPK and in-vivo models in multiple therapeutic areas. o2h discovery doesn’t have an animal facility, the in-life phase for PK studies as well as in-vivo efficacy studies are done with CROs with whom we have a preferred relationship for the past several years.

o2h discovery has strategic ties with several CROs in India and can help clients advance their projects to an IND application stage through chemical process scale-up and development (both GMP and non-GMP), bioanalytical studies, formulation approaches, safety-pharmacology and toxicology studies, clinical trial supplies, and medical writing. To know more about this, please write to us at

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative